News

Enobosarm's Promising Results in Weight Management Post-GLP-1

Enobosarm's Promising Results in Weight Management Post-GLP-1

Enobosarm Shows Positive Outcomes in Weight Management After Semaglutide

Veru Inc. (NASDAQ: VERU) has reported exciting findings from their recent clinical studies, focusing on Enobosarm, a drug with promising potential for weight management. The results highlight how Enobosarm can significantly mitigate weight regain and maintain lean mass after the discontinuation of semaglutide, a commonly used GLP-1 receptor agonist.

Study Overview and Methodology

In the Phase 2b QUALITY study and its maintenance extension, researchers examined the efficacy and safety of Enobosarm during a 12-week period post-semglutide treatment. The results indicate that the placebo group regained a striking 43% of the weight initially lost, whereas participants on Enobosarm had a 46% reduction in weight regain. This impressive outcome was accompanied by substantial preservation of lean mass and elimination of fat regain.

Findings on Fat Loss and Lean Mass Preservation

The findings suggest that not only does Enobosarm effectively combat weight regain, but it also enhances fat loss. Participants in the Enobosarm groups experienced an astounding fat loss of up to 93% while maintaining 100% lean mass preservation. This marks a significant advancement in obesity treatment, especially for those who may struggle with traditional weight-loss medications.

Safety Profile of Enobosarm

Safety is critical when considering any treatment. Throughout the study, Enobosarm monotherapy demonstrated a positive safety profile, with virtually no gastrointestinal side effects reported. This is particularly important given the concerns associated with many weight management therapies.

Insights from Medical Professionals

Dr. Mitchell Steiner, CEO of Veru, emphasized the importance of these results, noting that Enobosarm can offer individuals a meaningful way to sustain weight loss and improve body composition after stopping semaglutide. Moreover, Dr. Donna Ryan highlighted the dual benefits of muscle preservation and easier administration via oral means, reinforcing the drug's appeal especially among older populations at risk of muscle mass loss.

Future Prospects for Enobosarm

The positive outcomes from the Phase 2b studies have paved the way for further developments, including an upcoming meeting with the FDA to discuss the Phase 3 clinical program. This could be a significant step toward making Enobosarm a viable option in the weight management landscape.

Understanding the Clinical Study Design

After the active weight loss phase of the study, a total of 148 participants proceeded to the 12-week maintenance extension, where they received either placebo or Enobosarm in varying doses. The objective was to assess whether Enobosarm could effectively prevent the typical weight regain associated with stopping semaglutide treatment.

Substantial Evidence of Efficacy

The results indicated a remarkable capability of Enobosarm to curb both weight and fat regain while preserving lean muscle, a pivotal facet of obesity management. It provides a brighter outlook for those seeking sustainable weight loss solutions without sacrificing muscle mass.

Frequently Asked Questions

What is the main benefit of Enobosarm in weight management?

Enobosarm significantly reduces body weight regain and preserves lean mass after discontinuing semaglutide, making it an effective option for sustainable weight management.

How does Enobosarm compare to semaglutide?

While semaglutide is beneficial for weight loss, studies show that combining it with Enobosarm provides enhanced fat loss while maintaining lean mass, offering a more balanced approach to weight management.

What findings support Enobosarm's safety?

The Phase 2b studies revealed no significant gastrointestinal side effects or other serious adverse reactions, indicating a favorable safety profile for Enobosarm.

What future steps are planned for Enobosarm?

Veru plans to engage with the FDA regarding the Phase 3 clinical program, aiming to bring Enobosarm to market as a critical tool in weight management.

Why is muscle preservation important in weight loss?

Preserving lean muscle during weight loss is essential for maintaining metabolic health and physical function, especially in older adults, preventing the negative effects often associated with weight loss treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Zensar Sees Solid Revenue Growth in Q2FY27

Updated Category News Views 0

Zensar's Q2 Performance: Growth Amid Shifting Sands Is Zensar Technologies quietly carving a spot for itself in the cutthroat tech marketplace, or are we just seeing a temporary glimmer during a complex market scenario? With a constant currency growth rate of 4.1% in Q2FY27, Zensar sure seems to have gotten something right. But does this mean they’ve got the long-term...

Continue Reading
ElektraFi Challenges Starlink: Fixed Wireless Gains Edge

Updated Category News Views 0

Revolution or Just Better Options? In the wild west of internet connectivity, where every home is a frontier, ElektraFi is throwing down the gauntlet at the feet of behemoths like Starlink. They're talking big about their fixed wireless network, and in places stretching from Colorado's ski slopes to the dustier reaches of Texas, that talk might just hold some weight. Why...

Continue Reading
RD Technologies Ramps Up Cross-Border Payments

Updated Category News Views 160

RD Technologies: Revving Up the Payment Game RD Technologies is at it again, jazzing up its game in the cross-border payments realm. One can almost smell the digits doing a tango across continents—particularly as Hong Kong's financial warriors set their sights on beefing up trade between Africa and Asia. New Alliances in the Payment Arena Here's a roadmap: Connect the...

Continue Reading
Investcorp's Strong 2026: A Deep Dive into Key Moves

Updated Category News Views 159

Diving into Investcorp's Robust 2026 Performance If you're clued into the investment scene, you'll know that a $65.2 billion asset base isn't small potatoes. At the Gateway Gulf 2026, Investcorp didn't just present numbers—they laid out a dramatic year of action packed with billion-dollar dreams. While the dust hasn't quite settled yet, the first nine months of the year...

Continue Reading
Ebix and intentyx Tackle AI Security in Regulated Fields

Updated Category News Views 6

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

Continue Reading
Celebree's Gratitude Push: Kindness Turns into Action

Updated Category News Views 0

Expressing Gratitude: More than Just Words Gratitude: it's one of those feel-good concepts that everyone nods to, but let's face it—most folks don't really go beyond the occasional 'thanks.' That's where the Generation Gratitude Project by Celebree School steps in. The idea's not just about saying thanks, but about making it a real, action-oriented habit. This campaign,...

Continue Reading
Tactical Comm Market: $19.39B by 2031 Amid 8.1% CAGR

Updated Category News Views 49

Riding the Tactical Communication Wave Alright, here’s something to chew on over your morning coffee. The tactical communication market is projected to balloon from USD 13.14 billion in 2026 to a whopping USD 19.39 billion by 2031. That’s an 8.1% CAGR if you’re keeping track—no small peanuts. So what's driving this surge? It’s all about security, modernization,...

Continue Reading
Lazard Closes Deal with Campbell, Launches Lazard CL

Updated Category News Views 59

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

Continue Reading
XPENG Gears Up for Q3 2026 Results Amid AI Advancements

Updated Category News Views 70

XPENG's Upcoming Financial Disclosure XPENG Inc., a name that rings bells in the smart mobility world, is setting the stage for its third quarter 2026 financial results on November 16. Someone with a sharp enough gut could probably see it a mile away—these numbers might just be the ticket for a ride amid XPENG's high wire AI advancements. But let's not kid ourselves;...

Continue Reading
Pak Mail Jonesboro Dominates at Annex Brands Convention

Updated Category News Views 0

Small Town, Big Impact at the Annex Brands Shindig From little Jonesboro, Arkansas, comes a thunderous clap for the Kincades, who bagged a bunch of trophies and accolades at the big 2026 Annex Brands National Convention. Tim and Rhonda Kincade, the ones running Pak Mail Jonesboro, didn't just show up—they brought home the bacon with honors piled as high as the Ozarks....

Continue Reading

Top 5 Most Recently Viewed Articles

Grace Design Studios Expands Healthcare Expertise with CRGA

Updated Category News Views 375

Grace Design Studios Expands Its Healthcare Footprint Grace Design Studios, a prominent player in the architecture, engineering, and consulting arena, has successfully acquired CRGA Design, a firm recognized for its expertise in healthcare facility design. This strategic move significantly enhances Grace's capabilities while strengthening its presence across various...

Continue Reading
FlashStart Unveils World's Fastest DNS Filter, According to DNSperf

Updated Category News Views 500

FlashStart Launches Advanced DNS Filter FlashStart, a leader in internet security solutions, is proud to announce the release of its groundbreaking DNS filter, reputed to be the fastest in the world, as confirmed by DNSperf. This innovative solution is currently utilized by various organizations, educational institutions, and government entities across multiple countries....

Continue Reading
WeRide Launches Innovative Fare-Charging Robobus Service

Updated Category News Views 248

WeRide Unveils First Fare-Charging Level-4 Robobus Service WeRide has made significant progress by launching its first fare-charging Level-4 robobus service in the vibrant city of Guangzhou. This initiative breaks new ground in the realm of autonomous public transit, showcasing the company's dedication to leading the autonomous driving technology sector. Transforming...

Continue Reading
Projected Growth of the Global Frozen Seafood Industry

Updated Category News Views 264

Overview of the Frozen Seafood Market Growth The frozen seafood market is undergoing significant transformation, with a valuation estimated at US$ 27.3 billion in 2022. This sector is on track to achieve a remarkable growth trajectory, reaching a projected value of US$ 42.9 billion by the early 2030s, driven by a compound annual growth rate (CAGR) of 5.3%. As freezing...

Continue Reading
Axsome Therapeutics Unveils Promising ADHD Treatment Trial Results

Updated Category News Views 169

Significant Breakthrough in ADHD Treatment Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company, recently reported remarkable outcomes from its FOCUS Phase 3 trial focusing on solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. This trial has validated the potential of solriamfetol, highlighting its...

Continue Reading